Y-shaped pegylated growth hormone injection (YPEG-rhGH) / Xiamen Amoytop Biotech - LARVOL DELTA

Long-Acting Growth Hormone Versus Daily Growth Hormone for Growth Hormone Deficiency Patients: A Network Meta-Analysis of Clinical Trials. (PubMed, Endocrinol Diabetes Metab) - "Once-weekly LAGH provides an effective frontline alternative to daily acting growth hormone, without compromising overall linear growth or safety, while displaying no differences in overall treatment discontinuation. Selection should be based on the patients' clinical profiles, specifically considering higher localized reactions with Somatrogon. Clinicians should adhere to formulation-specific sampling windows (2-5 days post dose for Lonapegsomatropin; 96 h for Somatrogon) to accurately monitor steady-state IGF-1 levels."

Clinical • Journal • Retrospective data • Review • Dermatology • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Pediatric) • Pain • Pediatrics • IGF1

Population pharmacokinetics/pharmacodynamics and safety of YPEG-rhGH in elderly subjects. (PubMed, Front Pharmacol) - "The safety and tolerability of YPEG-rhGH injections in elderly subjects were favorable. Clinical Trial Registration: identifier CTR20230176."

Clinical • Journal • PK/PD data • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • IGF1

A Trial of YPEG-rhGH in Children With Short Stature (clinicaltrials.gov) - P2 | N=78 | Completed | Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Idiopathic Short Stature • Small for Gestational Age • Turners Syndrome